Background
==========

Breast cancer (BC) is the most frequent cancer among women in the world. Triple negative breast cancer (TNBC) is a type of BC that does not express oestrogen receptors, progesterone receptors and epidermal growth factor receptors-2/Neu (HER2) and accounts for the 16% of BCs approximatively \[[@ref1], [@ref2]\]. Due to its lack of response to hormone and targeted therapies, the number of therapeutic opportunities is limited \[[@ref3], [@ref4]\]. TNBC patients are difficult to treat, with unfavourable prognosis and are generally administered with the standard chemotherapy. At the moment, novel treatment approaches, such as immunotherapy, as well the repurposing of old drugs currently used for indications other than TNBC, is under investigation. In this context, we have previously reviewed the preclinical and clinical anticancer efficacy and safety of beta blockers in TNBC \[[@ref5]\].

Drug repurposing is the application of an old drug to a new disease indication: this holds the promise of rapid clinical impact at a lower cost than de novo drug development \[[@ref6]\]. In oncology, where new treatments in the last years are becoming more expensive due to the introduction of innovative therapies such as targeted therapies and immunotherapies, there is an increased interest at the use of already clinically approved non-cancer drugs, off patent and with known targets, as possible cancer treatments \[[@ref7]\]. One study published by Pantziarka *et al* \[[@ref8]\], point the spotlight on this matter building up a project about drug repurposing in the treatment of cancer. The REpurposing Drugs in Oncology (ReDO) project investigates the potential use of licensed non-cancer medications as sources of new cancer strategies. ReDO project has used a literature-based approach to identify licensed non-cancer drugs with published evidence of anticancer activity. At present, data of 268 drugs have been included in the REDO database (ReDO_DB) \[[@ref8]\].

In line with this project, we searched in PubMed for published preclinical or clinical evidence of anticancer activity for all drugs included in the ReDO_DB for TNBC. Specifically, starting from each drug present in ReDO_DB, we searched in PubMed for published preclinical and clinical evidence of anticancer activity for TNBC. The strings were composed by the name of the drugs and specific keywords related to TNBC.

An additional search string was used to investigate potential clinical evidence about drugs not included in ReDO_DB or references not retrieved in the first search. The string was composed by three blocks concerning keywords related to TNBC, repurposing and study type, respectively. Both strings are provided in the supplementary file ([Table S1](#tableS1){ref-type="table"}). Observational or clinical trials for which a TNBC cohort was defined were included. The articles that were not written in English were excluded.

Moreover, clinicaltrials.gov \[[@ref9]\] was searched for ongoing or completed clinical studies on drug repurposing and TNBC. All searches were performed on March 2019, and the information extracted were the following: 1) preclinical studies: number of studies per drug and pharmacological activity; 2) clinical studies: study type, country, study period, population studies, exclusion criteria, age, follow up, arms, treatments and outcomes; 3) clinicaltrials.gov: number of studies per drug.

The aim of this paper is to give to clinicians and scientists a comprehensive overview about preclinical and clinical studies, including clinical trials, present in literature on the repurposing of old-licensed drugs for TNBC.

We found 188 preclinical studies references (see Supplementary Material), 18 clinical references \[[@ref10]--[@ref26]\] and 16 references on clinical trials.gov on drug repurposing for TNBC \[[@ref9]\].

Preclinical studies
-------------------

Using the PubMed database, we found preclinical evidence on TNBC models (cell lines and xenograft models of TNBC) for 84 out of 268 old drugs (31.3%) present in the ReDO_DB. For 42 of the 84 drugs, only one reference was retrieved ([Table S2](#tableS2){ref-type="table"}). Thirteen studies referred to the anti-proliferative, pro-apoptotic and immune-stimulating effects of metformin, thirteen to the cytotoxic and anti-metastatic effects of chloroquine, eleven to the anti-proliferative and anti-invasive effects of simvastatin, eight to the anti-inflammatory and anti-angiogenic effects of acid acetylsalicylic and eight studies to the anti-angiogenic, anti-proliferative and anti-apoptotic effects of zoledronic acid. Main indications for drugs with preclinical evidence of efficacy on TNBC model were various and heterogeneous including epilepsy, analgesia, hypertension, diabetes, insomnia and other.

Clinical studies
----------------

[Table 1](#table1){ref-type="table"} shows all 17 clinical references collected (the article of Spera *et al* analyses two different retrospective studies on beta blockers efficacy and safety on TNBC \[[@ref13]\], and the articles of Hagasewa *et al* \[[@ref15]\] and Ishikawa *et al* \[[@ref16]\] analysed the same cohort of patients). Clinical evidence on twelve licensed drugs was found, and of these drugs, eleven out of 268 (4.1%) were included in ReDO_DB. Eleven studies out of 18 were retrospective studies \[[@ref10]--[@ref13], [@ref17], [@ref19], [@ref20], [@ref22], [@ref25], [@ref26]\], six were phase II and \[[@ref14]--[@ref16], [@ref18], [@ref21], [@ref23]\] one was a phase I clinical trial \[[@ref24]\] (see [Figure 1](#figure1){ref-type="fig"} for more details). Retrospective studies ranged from 1995 to 2016, and six out of eleven studies analysed a USA cohort of patients \[[@ref10], [@ref12], [@ref19], [@ref20], [@ref25], [@ref26]\]. Eight studies were performed using medical records \[[@ref10], [@ref12], [@ref17], [@ref19], [@ref20], [@ref22], [@ref25], [@ref26]\], one was based on disease registries \[[@ref11]\] and two reported the results of previous clinical trials \[[@ref13]\]. Of the 18 clinical studies collected, four analysed the efficacy of beta blockers (BB) \[[@ref11]--[@ref13]\], five of non-steroidal anti-inflammatory drugs (NSAIDs) \[[@ref17]--[@ref21]\], two of zoledronic acid \[[@ref15], [@ref16]\], one of metformin \[[@ref10]\], one of tetramolybdate \[[@ref14]\], one of itraconazole \[[@ref22]\], one of esomeprazole \[[@ref23]\], one of mifepristone \[[@ref24]\] and two of statins \[[@ref25], [@ref26]\]. Outcomes retrieved from clinical studies were grouped, whenever possible, in pharmacological categories and summarised in [Table 2](#table2){ref-type="table"}.

### Beta blockers (BBs)

BBs were evaluated on postmenopausal women with operated early primary TNBC, on women with invasive TNBC (receiving neoadjuvant chemotherapy), and on women with advanced or nodal positive TNBC. Study populations ranged from 35 patients to 1,417 patients. In the study of Melhem-Bertrandt *et al* \[[@ref12]\], using medical chart and pharmacy data from the Breast Cancer Management System Database in the USA, women with invasive TNBC receiving neoadjuvant chemotherapy plus BBs were compared to patients receiving only neoadjuvant chemotherapy between 1995 and 2007. Hazard ratio of recurrence free survival for women administered with chemotherapy plus BBs was 0.30 (95% CI, 0.10--0.87; *p* = 0.027) and hazard ratio of overall survival was 0.35 (95% CI, 0.12--1.00; *p* = 0.05) \[[@ref12]\]. Also, in the retrospective study of Botteri *et al* \[[@ref11]\] using Breast Cancer and Cardiology Division Databases in Italy and analysing 800 postmenopausal women diagnosed and operated for early primary TNBC between 1997 and 2008, BB users showed significant benefit when compared to not BB users. Breast cancer related events where lower in BB users (13.6% versus 27.9%; *p* = 0.02) and hazard ratio of metastasis and BC death were significant (0.32: 95% CI 0.12--0.90; *p* = 0.031; 0.42: 95% CI 0.18--0.97; *p* = 0.042, respectively). The study of Spera *et al* \[[@ref13]\], using data of a randomised, double blind clinical trial (ROSE/TRIO-012), showed significant benefit in women with advanced TNBC using BBs when compared to not users about progression free survival (Hazard ratio = 0.52; 95% CI, 0.34--0.80; *p* = 0.002) but not in overall survival (Hazard ratio = 0.87; 95% CI 0.58--1.31; *p* = 0.504). The second study presented by Spera *et al* \[[@ref13]\] using also data from another randomised, double blind clinical trial (BCIRG-005) about women with node positive TNBC did not show any significant benefit of relapse free survival and overall survival (Hazard ratio = 0.69; 95% CI, 0.35--1.34; *p* = 0.269; 0.73; 95% CI, 0.35--1.48; *p* = 0.38, respectively).

### Metformin

The retrospective study of Bayraktar *et al* \[[@ref10]\] using medical chart and pharmacy data from the Breast Cancer Management System Database compared women who received adjuvant chemotherapy with or without metformin in the USA between 1995 and 2007. In total, 1,448 patients (63 diabetic patients receiving metformin, 67 diabetic patients not receiving metformin and 1318 not diabetic patients). The 5 years survival estimates for distant metastasis free survival were 73% in the metformin group, 66% in the non-metformin group and 60% in the non-diabetic group (*p* = 0.23). Overall survival was 67% in the metformin group, 69% in the non-metformin group and 66% in the non-diabetic group (*p* = 0.58). Recurrence free survival was 65% in the metformin group, 64% in the non-metformin group and 54% in the non-diabetic group (0.38). Also, after adjustments, no significant survival outcomes were obtained.

### Tetramolybdate

The primary endpoint of phase II open label single arm study of Chan *et al* \[[@ref14]\] was to assess the change in VEGFR2+ endothelial progenitor cells in women treated with tetrathiomolybdate. The study, performed on 36 women with stage II/III TNBC during adjuvant setting, showed that two year event free survival was 90%.

### Zoledronic acid

The articles of Hasegawa *et al* \[[@ref15]\] and Ishikawa \[[@ref16]\] referred to the same phase II, open label, randomised study but analysed different outcomes in the same cohort of patients (34 women with stage IIA/IIIB TNBC) treated with zoledronic acid plus chemotherapy versus chemotherapy in neoadjuvant setting. Pathological complete response was not significant (*p* = 0.112) when comparing neoadjuvant chemotherapy plus zoledronic acid (6/17 (35.3%) CI: 12.6--58.0) with chemotherapy alone (2/17 (11.8%) CI: 0.0--27.1). Also for the 3 years disease free survival, neoadjuvant chemotherapy plus zoledronic acid showed no significant benefit compared to the neoadjuvant treatment alone (*p* = 0.077) despite the fact that the percentage of patients in treatment with zoledronic acid was higher compared to the other arm (94.1% versus 70.6%).

### NSAIDs

Celecoxib was analysed in two studies: the first, a phase II randomised study of Pierga *et al* \[[@ref21]\] performed between 2004 and 2007, analysed 23 women with stage II/III TNBC comparing chemotherapy alone with chemotherapy plus celecoxib. The authors stated that celecoxib did not improve pathological complete response rates, but no specific comparison on this outcome were shown in the article for TNBC patients. The second study, a phase II multicentre open-label single arm study of Chow *et al* \[[@ref18]\], analysed women with primary breast cancer. Unfortunately, only two patients with primary TNBC were included and authors could not show any result about this cohort.

Aspirin was analysed in two retrospective studies. The first retrospective study of Shiao *et al* \[[@ref19]\] that collected medical records from University of Texas Southwestern TNBC registry, analysed a cohort of 222 women with stage II/III TNBC in the USA between 2005 abd 2013. Sixty-five women were treated with anti-platelet therapy (as aspirin or clopidogrel) and 157 with no anti-platelet therapy. A percentage of patients in both arms (6.3% and 7.1%, respectively) did not receive chemotherapy. Five years disease free survival and 5 years distant metastasis hazard ratios was significantly improved in favour of the first arm (anti-platelet 80.4%, no anti-platelet 62.3%, HR: 0.503 (0.261--0.970); *p* = 0.04; anti-platelet 8.8%, no anti-platelet 31.9%, HR: 0.310 (0.132--0.729); *p* = 0.007, respectively). Five years overall survival hazard ratio was not significant between the two arms (HR: 0.652 (0.343--1.239); *p* = 0.192). The second retrospective study of Williams *et al* \[[@ref20]\] performed in USA used electronic medical records of 147 women with primary operable stages I-III TNBC (114 never used aspirin, 19 before diagnosis, and 14 after diagnosis) to analyse overall survival and disease-free survival between 2005 and 2013. Results of this study indicated that aspirin may have an impact on the pathogenesis of TNBC but do not seem to affect breast cancer survival when used after cancer diagnosis (results were presented only for the total cohort of breast cancer patients and not for TNBC subtype).

Finally, Retsky *et al* \[[@ref17]\] showed the updated results of a retrospective study performed in Belgium using medical records between 2003 and 2008 \[[@ref27]\], in which ketorolac plus chemotherapy was compared to chemotherapy alone in women who underwent mastectomy with axillary dissection. No information about the cohort (as for the number of patients with TNBC, age, etc...) was reported. Also, for the results the authors said that the group receiving chemotherapy plus ketorolac showed a 'far superior disease free survival in the first few years after surgery' but no data were shown in particular about TNBC.

### Itraconazole

The article of Tsubamoto *et al* \[[@ref22]\] reported the results of a retrospective study that used medical records of the Kohan hospital in Japan between 2008 and 2012 to analye response rate, median progression-free survival and median overall survival of thirteen patients. TNBC patients who progressed after prior chemotherapy were treated with chemotherapy in combination with itraconazole. No comparison was made. The authors showed that response rate was 62% (\[CI\], 35%--88%), progression free survival was 10.8 months (95%CI, 7.6--15.3) and overall survival was 20.4 months (95%CI: 13.1--41.4 months).

### Esomeprazole

The phase II, open label, randomised study of Wang *et al* \[[@ref23]\] analysed a cohort of 15 women with metastatic or recurrent TNBC (seven receiving only chemotherapy, two esomeprazole low dose and six esomeprazole high dose). The authors showed that the time to progression of patients receiving esomeprazole when compared to chemotherapy was significantly higher (10.7 versus 5.8 months; *p* = 0.011).

### Mifepristone

In the Phase I, randomised study of Nanda and colleagues performed in USA, four women with metastatic or locally advanced TNBC were analysed (those patients were allocated to mifepristone plus paclitaxel or placebo). Unfortunately, no information about patients allocation, nor any outcome information could be retrieved from this article \[[@ref24]\].

### Statins

The retrospective study of Shaitelman *et al* \[[@ref26]\] used medical records from the MD Anderson Cancer Centre to investigate if women with stage I--III TNBC receiving statins at any time from diagnosis. The authors showed that patients receiving statins did not get any advantage compared to the non-statin users group (0.82 (0.57--1.16); 0.70 (0.47--1.03) relative risk of recurrence and breast cancer death, respectively); when a multivariate analysis was performed (taking in consideration cholesterol and triglyceride values, stage and chemotherapy, the authors showed that statin use was predictive for OS (HR: 0.10, *p* = 0.026, 95% CI: 0.01--0.76).

The retrospective study of Lacerda *et al* \[[@ref25]\] using Breast Cancer Management database at MD Anderson Cancer Centre in USA between 1995 and 2011, analysed the risk of loco-regional recurrence at 3 years associated to the use of statins, in patients with inflammatory breast cancer who received adjuvant post-mastectomy radiotherapy. 102 patients underwent post-mastectomy radiation (86 patients) or post-mastectomy radiation plus statins (16 patients). Unfortunately no information about the outcome in TNBC patients was shown.

Clinicaltrials.gov
------------------

Searching the web site of clinicaltrials.gov (clinicaltrials.gov), we found only 17 drugs out of 286 presented in the ReDo_DB with ongoing or completed clinical trials for TNBC. [Table 3](#table3){ref-type="table"} shows the list of trials and the recruitment status for each drug. As shown in [Table 3](#table3){ref-type="table"}, most part of the drugs present only one or few studies published on this website. In total, three studies are recruiting for the assessment of atorvastatin, two for metformin, two for mifepristone, and three for zoledronic acid.

Future directions
=================

This review presents an overview of all the evidences about the repurposing of old, licensed, non-cancer-drugs in the treatment of TNBC, starting from preclinical evidence and going through current clinical trials. ReDO is an ambitious project aiming to investigate the repurposing of non-cancer-drugs in oncology, and ReDO_DB is a powerful tool that need to be dynamically implemented with recent findings, by adding to the database new drugs for which there are preclinical evidence, and by giving visitors a specific PubMed search string for each tumour and tumour subtypes. The ReDO approach is based on published literature and does not aim to identify new active compounds against cancer. Thus, the database does not include potential repurposing candidates identified through *in silico* modelling or other computational pharmacological approaches that, despite the interest for the research \[[@ref28]--[@ref31]\], unless validated by preclinical studies, represent only future hypothetical repurposed drugs and far from the aim of the ReDO project. The project, in particular, aims to drive scientist attention to investigate already approved non cancer-drugs in the oncology setting. Using this ReDO_DB, we found out that despite a lot of preclinical evidence was produced for drugs included in the database for the treatment of TNBC, only few of them were tested in clinical trials. Moreover, in clinical trials only few of the studies used a large sample of cases and gave explicit results on the repurposing of old drugs for TNBC. Some of the studies did not report any result for TNBC cohort when this is a part of a bigger BC cohort.

Beta Blockers (BBs) seem to be the more promising drugs in the repurposing for the treatment of TNBC. Three articles showed significant benefits of these drugs in women with advanced TNBC and in early primary TNBC patients treated with the combination of chemotherapy plus BBs \[[@ref11]--[@ref13]\]. Unfortunately, in clinicaltrials.gov we found no studies that specifically attempt to evaluate BBs within clinical trials for TNBC patients. One triple blinded phase II randomised trial evaluated the use of pre-operative propranolol (seven days before surgery) compared to placebo in 60 women with early stage surgically-resectable breast cancer. \[[@ref32]\]. The authors showed that the treatment with propranolol reduced intra-tumoral mesenchymal transition and promoted immune cell infiltration reducing biomarkers associated with metastatic potential. Unfortunately, authors did not present results stratified for breast cancer sub-type.

While BBs demonstrated to be beneficial in the treatment of TNBC, metformin, a promising molecule in preclinical studies, did not show any efficacy in the treatment of women with TNBC. Bayraktar *et al* \[[@ref10]\] showed that metformin does not improve survival outcomes in a population of TNBC women when compared to not users. Of note, two studies on the use of metformin in clinicaltrials.gov on TNBC patients are ongoing.

The articles of Shiao *et al* \[[@ref19]\] and Williams *et al* \[[@ref20]\] showed conflicting results on aspirin. While the first study showed a significant survival benefit in women with stage II/III by the use of aspirin, Williams *et al* \[[@ref20]\] did not show this benefit in the breast cancer population examined (women with operable stage I-III TNBC).

Despite many studies trying to evaluate the use of statins in breast cancer treatment \[[@ref33]--[@ref36]\], in the literature search on PubMed, we retrieved only two retrospective studies on their use in the TNBC cohort. The article of Shaitelman *et al* \[[@ref26]\] reported a non-significant improvement of OS for patients in the statin group (with the exception of the multivariate analysis), while the second study of Lacerda *et al* \[[@ref25]\] did not show any results for TNBC patients.

Other authors showed significant results on the survival of TNBC patients treated with esomeprazole. Recently, one phase II study on activity of omeprazole on patients with operable TNBC independent of baseline Fatty acid synthase (FASN) expression was presented at the ASCO meeting. \[[@ref37]\] *In vitro*, proton pump inhibitors inhibit FASN activity and induce apoptosis in breast cancer cell lines. In this study, omeprazole in combination with anthracycline-taxane (AC-T) was administered to 42 patients until surgery, and pathologic complete response (pCR) was investigated. FASN positivity significantly decreased with omeprazole from 0.53 (SD = 0.25) at baseline to 0.38 (SD = 0.30; *p* = 0.02), and the drug was well tolerated with no known grade 3 or 4 toxicities. Furthermore, the pCR rate was 71.4% (95% CI: 51.3--86.8) in FASN+ patients and 71.8 % (95% CI: 55.1--85.0) in all enrolled patients, demonstrating that the omeprazole in addition to neoadjuvant AC-T yields a promising pCR rate without adding toxicity.

For those drugs collected in ReDO_DB with favourable preclinical evidence or whose retrospective clinical trials were not so large to provide strong evidence, large retrospective cohort studies are needed to evaluate effectiveness. Further, as for BBs that have proven by retrospective studies to be effective in the treatment of TNBC patients, randomised clinical trials might be important to confirm the evidence of the repurposing.

Final remarks
=============

Drug repurposing is a highly interesting novel strategy for the oncology community and ReDO_DB is a powerful tool that can give authors the opportunity to investigate weather non-anticancer drugs might be effective in cancer treatment. Some precision medicine studies, based on omics data, have included repurposed drugs and have reported interesting case reports of responses from patients \[[@ref38], [@ref39]\], however no one on TNBC. Due to the low number of therapeutic opportunities approved for TNBC, repurposing of old drugs seems a valuable approach for this particular type of cancer.

From the literature retrieved, BBs seemed to be the more promising drugs for the repurposing, while evidence about other drugs as NSAIDs still need to be assessed or proven for the treatment of TNBC.

Conflicts of interest
=====================

The authors declare that they have no conflict of interest

Authors\' contributions
=======================

MZ and SC conceived the study. AS extracted the data. SD supervised the data extraction. MZ, SD, SC, AS, and PP contributed to the interpretation and discussion of study results. AS and SD drafted the manuscripts. All authors revised and approved the final version of the paper.

Funding
=======

This study was supported by Fondazione Decima Regio 'Olga e Raimondo Curri', Via Cimarra 44-B, Roma.

Supplementary tables
====================

###### Search strings.

  -----------------------------------------------------------------------------------------------------------------------------------
  **PubMED String: 3 blocks combined with AND**
  Pathology block
  \"Triple negative breast cancer\"\[Title/Abstract\] OR \"TNBC\"\[Title/Abstract\] OR \"Triple negative breast neoplasms\"\[Mesh\]
  Intervention Block
  \"Repurposing\"\[All Fields\] OR \"Repurpose\"\[All Fields\] OR \"Repositioning\"\[All fields\] OR \"Reposition\"\[All Fields\]
  Type of study Block
  \"Clinical trial\"\[Publication type\] OR \"Clinical Study\"\[Publication Type\] OR \"Epidemiologic Studies\"\[Mesh\]
  **PubMED sting based on ReDO_DB: 2 blocks combined with AND**
  Drugs block: all the drugs and their synonyms in the Redo Database
  Pathology block
  \"Triple negative breast cancer\"\[Title/Abstract\] OR \"TNBC\"\[Title/Abstract\] OR \"Triple negative breast neoplasms\"\[Mesh\]
  -----------------------------------------------------------------------------------------------------------------------------------

###### Preclinical references for repurposing of drugs for TNBC by ReDO DB.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Drugs                  Main indication                                                                                                          Mechanism of action                                                                References
  ---------------------- ------------------------------------------------------------------------------------------------------------------------ ---------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Acetaminophen          Analgesia                                                                                                                TRPA1 inhibitor                                                                    --Afshar E, Hashemi-Arabi M, Salami S, Peirouvi T, Pouriran R. Screening of acetaminophen-induced alterations in epithelial-to-mesenchymal transition-related expression of microRNAs in a model of stem-like triple-negative breast cancer cells: The possible functional impacts. Gene. 2019 Jun 20;702:46--55.

  Acetazolamide          Glaucoma, diuretic, epilepsy                                                                                             Carbonic anhydrase inhibitor                                                       --Ivanova L, Zandberga E, Siliņa K, Kalniņa Z, Ābols A, Endzeliņš E, et al. Prognostic relevance of carbonic anhydrase IX expression is distinct in various subtypes of breast cancer and its silencing suppresses self-renewal capacity of breast cancer cells. Cancer Chemother Pharmacol. 2015 Feb;75(2):235--46\
                                                                                                                                                                                                                                     --Tatiparti K, Sau S, Gawde KA, Iyer AK. Copper-Free "Click" Chemistry-Based Synthesis and Characterisation of Carbonic Anhydrase-IX Anchored Albumin-Paclitaxel Nanoparticles for Targeting Tumor Hypoxia. Int J Mol Sci. 2018 Mar 13;19(3).

  Acetylsalicylic acid   Analgesia, swelling, prophylaxis of venous embolism and further heart attacks or strokes                                 Cyclooxygenase inhibitor                                                           --Bhardwaj A, Singh H, Trinidad CM, Albarracin CT, Hunt KK, Bedrosian I. The isomiR-140-3p-regulated mevalonic acid pathway as a potential target for prevention of triple negative breast cancer. Breast Cancer Res. 2018 11;20(1):150.\
                                                                                                                                                                                                                                     --Amaral MEA, Nery LR, Leite CE, de Azevedo Junior WF, Campos MM. Pre-clinical effects of metformin and aspirin on the cell lines of different breast cancer subtypes. Invest New Drugs. 2018;36(5):782--96.\
                                                                                                                                                                                                                                     --Talarico G, Orecchioni S, Dallaglio K, Reggiani F, Mancuso P, Calleri A, et al. Aspirin and atenolol enhance metformin activity against breast cancer by targeting both neoplastic and microenvironment cells. Sci Rep. 2016 Jan 5;6:18673.\
                                                                                                                                                                                                                                     --Maity G, Chakraborty J, Ghosh A, Haque I, Banerjee S, Banerjee SK. Aspirin suppresses tumor cell-induced angiogenesis and their incongruity. J Cell Commun Signal. 2019 Jan 4\
                                                                                                                                                                                                                                     --Hsieh C-C, Wang C-H. Aspirin Disrupts the Crosstalk of Angiogenic and Inflammatory Cytokines between 4T1 Breast Cancer Cells and Macrophages. Mediators Inflamm. 2018;2018:6380643\
                                                                                                                                                                                                                                     --Basudhar D, Glynn SA, Greer M, Somasundaram V, No JH, Scheiblin DA, et al. Coexpression of NOS2 and COX2 accelerates tumor growth and reduces survival in estrogen receptor-negative breast cancer. Proc Natl Acad Sci USA. 2017 05;114(49):13030--5\
                                                                                                                                                                                                                                     --Lee YR, Kim KM, Jeon BH, Choi S. Extracellularly secreted APE1/Ref-1 triggers apoptosis in triple-negative breast cancer cells via RAGE binding, which is mediated through acetylation. Oncotarget. 2015 Sep 15;6(27):23383--98\
                                                                                                                                                                                                                                     --Chattopadhyay M, Kodela R, Nath N, Barsegian A, Boring D, Kashfi K. Hydrogen sulfide-releasing aspirin suppresses NF-κB signaling in estrogen receptor negative breast cancer cells in vitro and in vivo. Biochem Pharmacol. 2012 Mar 15;83(6):723--32

  Albendazole            Parasitic infection                                                                                                      Tubulin polymerisation inhibitor                                                   --Priotti J, Baglioni MV, García A, Rico MJ, Leonardi D, Lamas MC, et al. Repositioning of Anti-parasitic Drugs in Cyclodextrin Inclusion Complexes for Treatment of Triple-Negative Breast Cancer. AAPS PharmSciTech. 2018 Nov;19(8):3734--41.

  Amiloride              In congestive heart failure or hypertension treated with thiazides, to conserve potassium                                Sodium channel blocker                                                             --Amith SR, Wilkinson JM, Baksh S, Fliegel L. The Na⁺/H⁺ exchanger (NHE1) as a novel co-adjuvant target in paclitaxel therapy of triple-negative breast cancer cells. Oncotarget. 2015 Jan 20;6(2):1262-75.

  Aprepitant             Nausea, vomiting                                                                                                         Tachykinin antagonist                                                              --Robinson P, Kasembeli M, Bharadwaj U, Engineer N, Eckols KT, Tweardy DJ. Substance P Receptor Signaling Mediates Doxorubicin-Induced Cardiomyocyte Apoptosis and Triple-Negative Breast Cancer Chemoresistance. Biomed Res Int. 2016;2016:1959270

  Artesunate             Malaria                                                                                                                  DNA synthesis inhibitor                                                            --Greenshields AL, Fernando W, Hoskin DW. The anti-malarial drug artesunate causes cell cycle arrest and apoptosis of triple-negative MDA-MB-468 and HER2-enriched SK-BR-3 breast cancer cells. Exp Mol Pathol. 2019;107:10--22.

  Ascorbic acid          Scurvy                                                                                                                   Antioxidant                                                                        --Wu C-W, Liu H-C, Yu Y-L, Hung Y-T, Wei C-W, Yiang G-T. Combined treatment with vitamin C and methotrexate inhibits triple-negative breast cancer cell growth by increasing H2O2 accumulation and activating caspase-3 and p38 pathways. Oncol Rep. 2017 Apr;37(4):2177--84.\
                                                                                                                                                                                                                                     --Hatem E, Azzi S, El Banna N, He T, Heneman-Masurel A, Vernis L, et al. Auranofin/Vitamin C: A Novel Drug Combination Targeting Triple-Negative Breast Cancer. J Natl Cancer Inst. 2018 Nov 20.

  Atenolol               Hypertension, angina pectoris                                                                                            Adrenergic receptor antagonist                                                     --Talarico G, Orecchioni S, Dallaglio K, Reggiani F, Mancuso P, Calleri A, et al. Aspirin and atenolol enhance metformin activity against breast cancer by targeting both neoplastic and microenvironment cells. Sci Rep. 2016 Jan 5;6:18673

  Atorvastatin           Coronary heart disease, acute coronary syndrome                                                                          HMGCR inhibitor                                                                    --Rachner TD, Göbel A, Thiele S, Rauner M, Benad-Mehner P, Hadji P, et al. Dickkopf-1 is regulated by the mevalonate pathway in breast cancer. Breast Cancer Res. 2014 Feb 14;16(1):R20\
                                                                                                                                                                                                                                     --Mafuvadze B, Liang Y, Hyder SM. Cholesterol synthesis inhibitor RO 48-8071 suppresses transcriptional activity of human estrogen and androgen receptor. Oncol Rep. 2014 Oct;32(4):1727--33\
                                                                                                                                                                                                                                     --Koohestanimobarhan S, Salami S, Imeni V, Mohammadi Z, Bayat O. Lipophilic statins antagonistically alter the major epithelial-to-mesenchymal transition signaling pathways in breast cancer stem-like cells via inhibition of the mevalonate pathway. J Cell Biochem. 2018 Sep 6.

  Auranofin              RA                                                                                                                       NFkB pathway inhibitor                                                             --Raninga PV, Lee AC, Sinha D, Shih Y-Y, Mittal D, Makhale A, et al. Therapeutic cooperation between auranofin, a thioredoxin reductase inhibitor and anti-PD-L1 antibody for treatment of triple-negative breast cancer. Int J Cancer. 2019 May 15\
                                                                                                                                                                                                                                     --Hatem E, Azzi S, El Banna N, He T, Heneman-Masurel A, Vernis L, et al. Auranofin/Vitamin C: A Novel Drug Combination Targeting Triple-Negative Breast Cancer. J Natl Cancer Inst. 2018 Nov 20

  Azithromycin           Bacterial infection, CAP, PID                                                                                            Bacterial 50S ribosomal subunit inhibitor                                          

  Bazedoxifene           Osteoporosis                                                                                                             selective estrogen receptor modulator (SERM)                                       --Fu S, Lin J. Blocking Interleukin-6 and Interleukin-8 Signaling Inhibits Cell Viability, Colony-forming Activity, and Cell Migration in Human Triple-negative Breast Cancer and Pancreatic Cancer Cells. Anticancer Res. 2018 Nov;38(11):6271--9\
                                                                                                                                                                                                                                     --Fu S, Chen X, Lo H-W, Lin J. Combined bazedoxifene and paclitaxel treatments inhibit cell viability, cell migration, colony formation, and tumor growth and induce apoptosis in breast cancer. Cancer Lett. 2019 Apr 28;448:11--9.\
                                                                                                                                                                                                                                     --Tian J, Chen X, Fu S, Zhang R, Pan L, Cao Y, et al. Bazedoxifene is a novel IL-6/GP130 inhibitor for treating triple-negative breast cancer. Breast Cancer Res Treat. 2019 Jun;175(3):553--66

  Bepridil               Hypertension and chronic stable angina                                                                                   Calcium channel blocker                                                            --Park S-H, Chung YM, Ma J, Yang Q, Berek JS, Hu MC-T. Pharmacological activation of FOXO3 suppresses triple-negative breast cancer in vitro and in vivo. Oncotarget. 2016 Jul 5;7(27):42110--25.
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                                                                                                                                                                                                                                     --Skor MN, Wonder EL, Kocherginsky M, Goyal A, Hall BA, Cai Y, et al. Glucocorticoid receptor antagonism as a novel therapy for triple-negative breast cancer. Clin Cancer Res. 2013 Nov 15;19(22):6163--72.

  Minocycline            Antibiotic                                                                                                               Bacterial 30S ribosomal subunit inhibitor                                          --Himmel LE, Lustberg MB, DeVries AC, Poi M, Chen C-S, Kulp SK. Minocycline, a putative neuroprotectant, co-administered with doxorubicin-cyclophosphamide chemotherapy in a xenograft model of triple-negative breast cancer. Exp Toxicol Pathol. 2016 Oct;68(9):505--15.

  Montelukast            Allergies                                                                                                                Leukotriene receptor antagonist                                                    --Suknuntha K, Yubolphan R, Krueaprasertkul K, Srihirun S, Sibmooh N, Vivithanaporn P. Leukotriene Receptor Antagonists Inhibit Mitogenic Activity in Triple Negative Breast Cancer Cells. Asian Pac J Cancer Prev. 2018 Mar 27;19(3):833--7.

  Nelfinavir             Anti-retroviral                                                                                                          HIV protease inhibitor                                                             --Thomas S, Sharma N, Golden EB, Cho H, Agarwal P, Gaffney KJ, et al. Preferential killing of triple-negative breast cancer cells in vitro and in vivo when pharmacological aggravators of endoplasmic reticulum stress are combined with autophagy inhibitors. Cancer Lett. 2012 Dec 1;325(1):63--71.

  Niclosamide            Parasitic infection                                                                                                      DNA replication inhibitor\|STAT inhibitor                                          --Yin L, Gao Y, Zhang X, Wang J, Ding D, Zhang Y, et al. Niclosamide sensitizes triple-negative breast cancer cells to ionizing radiation in association with the inhibition of Wnt/β-catenin signaling. Oncotarget. 2016 Jul 5;7(27):42126--38.\
                                                                                                                                                                                                                                     --Liu J, Chen X, Ward T, Pegram M, Shen K. Combined niclosamide with cisplatin inhibits epithelial-mesenchymal transition and tumor growth in cisplatin-resistant triple-negative breast cancer. Tumour Biol. 2016 Jul;37(7):9825--35.\
                                                                                                                                                                                                                                     --Lu L, Dong J, Wang L, Xia Q, Zhang D, Kim H, et al. Activation of STAT3 and Bcl-2 and reduction of reactive oxygen species (ROS) promote radioresistance in breast cancer and overcome of radioresistance with niclosamide. Oncogene. 2018;37(39):5292--304.\
                                                                                                                                                                                                                                     --Pindiprolu SKSS, Chintamaneni PK, Krishnamurthy PT, Ratna Sree Ganapathineedi K. Formulation-optimisation of solid lipid nanocarrier system of STAT3 inhibitor to improve its activity in triple negative breast cancer cells. Drug Dev Ind Pharm. 2019 Feb;45(2):304--13.

  Nicotinamide           Niacin Deficiency, Skin cancer chemoprevention                                                                           Protein synthesis stimulant                                                        --Kim JY, Lee H, Woo J, Yue W, Kim K, Choi S, et al. Reconstruction of pathway modification induced by nicotinamide using multi-omic network analyses in triple negative breast cancer. Sci Rep. 2017 14;7(1):3466.

  Nimodipine             Hypertension                                                                                                             Calcium channel blocker                                                            --Jin U-H, Lee S-O, Pfent C, Safe S. The aryl hydrocarbon receptor ligand omeprazole inhibits breast cancer cell invasion and metastasis. BMC Cancer. 2014 Jul 9;14:498.

  Noscapine              Anti-tussive                                                                                                             Bradykinin receptor antagonist\|tubulin polymerisation inhibitor                   --Doddapaneni R, Patel K, Chowdhury N, Singh M. Noscapine chemosensitization enhances docetaxel anticancer activity and nanocarrier uptake in triple negative breast cancer. Exp Cell Res. 2016 01;346(1):65--73.\
                                                                                                                                                                                                                                     --Chougule MB, Patel AR, Jackson T, Singh M. Antitumor activity of Noscapine in combination with Doxorubicin in triple negative breast cancer. PLoS ONE. 2011 Mar 15;6(3):e17733.\
                                                                                                                                                                                                                                     --Doddapaneni R, Patel K, Chowdhury N, Singh M. Reversal of drug-resistance by noscapine chemo-sensitization in docetaxel resistant triple negative breast cancer. Sci Rep. 2017 Nov 20;7(1):15824.

  Omega 3                Hyperlipidemia                                                                                                                                                                                              --Pizato N, Luzete BC, Kiffer LFMV, Corrêa LH, de Oliveira Santos I, Assumpção JAF, et al. Omega-3 docosahexaenoic acid induces pyroptosis cell death in triple-negative breast cancer cells. Sci Rep. 2018 31;8(1):1952.\
                                                                                                                                                                                                                                     --Torres-Adorno AM, Vitrac H, Qi Y, Tan L, Levental KR, Fan Y-Y, et al. Eicosapentaenoic acid in combination with EPHA2 inhibition shows efficacy in preclinical models of triple-negative breast cancer by disrupting cellular cholesterol efflux. Oncogene. 2019;38(12):2135--50.\
                                                                                                                                                                                                                                     --Pizato N, Kiffer LFMV, Luzete BC, Assumpção JAF, Correa LH, Melo HAB de, et al. Omega 3-DHA and Delta-Tocotrienol Modulate Lipid Droplet Biogenesis and Lipophagy in Breast Cancer Cells: the Impact in Cancer Aggressiveness. Nutrients. 2019 May 28;11(6).\
                                                                                                                                                                                                                                     --Pogash TJ, El-Bayoumy K, Amin S, Gowda K, de Cicco RL, Barton M, et al. Oxidized derivative of docosahexaenoic acid preferentially inhibit cell proliferation in triple negative over luminal breast cancer cells. In Vitro Cell Dev Biol Anim. 2015 Feb;51(2):121--7\
                                                                                                                                                                                                                                     --Blanckaert V, Kerviel V, Lépinay A, Joubert-Durigneux V, Hondermarck H, Chénais B. Docosahexaenoic acid inhibits the invasion of MDA-MB-231 breast cancer cells through upregulation of cytokeratin-1. Int J Oncol. 2015;46(6):2649--55.

  Omeprazole             Antacid                                                                                                                  ATPase inhibitor                                                                   --Jin U-H, Lee S-O, Pfent C, Safe S. The aryl hydrocarbon receptor ligand omeprazole inhibits breast cancer cell invasion and metastasis. BMC Cancer. 2014 Jul 9;14:498.

  Orlistat               Obesity                                                                                                                  Lipase inhibitor                                                                   --Paulmurugan R, Bhethanabotla R, Mishra K, Devulapally R, Foygel K, Sekar TV, et al. Folate Receptor-Targeted Polymeric Micellar Nanocarriers for Delivery of Orlistat as a Repurposed Drug against Triple-Negative Breast Cancer. Mol Cancer Ther. 2016 Feb;15(2):221--31\
                                                                                                                                                                                                                                     --Bhargava-Shah A, Foygel K, Devulapally R, Paulmurugan R. Orlistat and antisense-miRNA-loaded PLGA-PEG nanoparticles for enhanced triple negative breast cancer therapy. Nanomedicine (Lond). 2016 Feb;11(3):235--47.

  Penfluridol            Psychotic disorders                                                                                                      T-type calcium channel blocker                                                     --Ranjan A, Gupta P, Srivastava SK. Penfluridol: An Antipsychotic Agent Suppresses Metastatic Tumor Growth in Triple-Negative Breast Cancer by Inhibiting Integrin Signaling Axis. Cancer Res. 2016 Feb 15;76(4):877--90.

  Pentamidine            Parasitic infection                                                                                                      Anti-pneumocystis agent                                                            --Her S, Cui L, Bristow RG, Allen C. Dual Action Enhancement of Gold Nanoparticle Radiosensitization by Pentamidine in Triple Negative Breast Cancer. Radiat Res. 2016;185(5):549--62

  Pentoxifylline         Peripheral artery disease                                                                                                Phosphodiesterase inhibitor                                                        --Castellanos-Esparza YC, Wu S, Huang L, Buquet C, Shen R, Sanchez-Gonzalez B, et al. Synergistic promoting effects of pentoxifylline and simvastatin on the apoptosis of triple-negative MDA-MB-231 breast cancer cells. Int J Oncol. 2018 Apr;52(4):1246--54

  Pirfenidone            Anti-fibrotic                                                                                                            TGF beta receptor inhibitor                                                        --Brooks D, Zimmer A, Wakefield L, Lyle LT, Difilippantonio S, Tucci FC, et al. Limited fibrosis accompanies triple-negative breast cancer metastasis in multiple model systems and is not a preventive target. Oncotarget. 2018 May 4;9(34):23462--81.\
                                                                                                                                                                                                                                     --Takai K, Le A, Weaver VM, Werb Z. Targeting the cancer-associated fibroblasts as a treatment in triple-negative breast cancer. Oncotarget. 2016 Dec 13;7(50):82889--901\
                                                                                                                                                                                                                                     --Qi X, Yin N, Ma S, Lepp A, Tang J, Jing W, et al. p38γ MAPK Is a Therapeutic Target for Triple-Negative Breast Cancer by Stimulation of Cancer Stem-Like Cell Expansion. Stem Cells. 2015 Sep;33(9):2738--47.

  Propranolol            Hypertension                                                                                                             Adrenergic receptor antagonist                                                     --Rico M, Baglioni M, Bondarenko M, Laluce NC, Rozados V, André N, et al. Metformin and propranolol combination prevents cancer progression and metastasis in different breast cancer models. Oncotarget. 2017 Jan 10;8(2):2874--89.\
                                                                                                                                                                                                                                     --Choy C, Raytis JL, Smith DD, Duenas M, Neman J, Jandial R, et al. Inhibition of β2-adrenergic receptor reduces triple-negative breast cancer brain metastases: The potential benefit of perioperative β-blockade. Oncol Rep. 2016 Jun;35(6):3135--42.\
                                                                                                                                                                                                                                     --Pasquier E, Ciccolini J, Carre M, Giacometti S, Fanciullino R, Pouchy C, et al. Propranolol potentiates the anti-angiogenic effects and anti-tumor efficacy of chemotherapy agents: implication in breast cancer treatment. Oncotarget. 2011 Oct;2(10):797--809.\
                                                                                                                                                                                                                                     --Xie W-Y, He R-H, Zhang J, He Y-J, Wan Z, Zhou C-F, et al. β‑blockers inhibit the viability of breast cancer cells by regulating the ERK/COX‑2 signaling pathway and the drug response is affected by ADRB2 single‑nucleotide polymorphisms. Oncol Rep. 2019 Jan;41(1):341--50.

  Pyrimethamine          Parasitic infection                                                                                                      Dihydrofolate reductase inhibitor                                                  --Egusquiaguirre SP, Yeh JE, Walker SR, Liu S, Frank DA. The STAT3 Target Gene TNFRSF1A Modulates the NF-κB Pathway in Breast Cancer Cells. Neoplasia. 2018;20(5):489--98.

  Riluzole               ALS                                                                                                                      Glutamate inhibitor                                                                --Speyer CL, Smith JS, Banda M, DeVries JA, Mekani T, Gorski DH. Metabotropic glutamate receptor-1: a potential therapeutic target for the treatment of breast cancer. Breast Cancer Res Treat. 2012 Apr;132(2):565--73.\
                                                                                                                                                                                                                                     --Speyer CL, Nassar MA, Hachem AH, Bukhsh MA, Jafry WS, Khansa RM, et al. Riluzole mediates anti-tumor properties in breast cancer cells independent of metabotropic glutamate receptor-1. Breast Cancer Res Treat. 2016;157(2):217--28.\
                                                                                                                                                                                                                                     --Speyer CL, Bukhsh MA, Jafry WS, Sexton RE, Bandyopadhyay S, Gorski DH. Riluzole synergizes with paclitaxel to inhibit cell growth and induce apoptosis in triple-negative breast cancer. Breast Cancer Res Treat. 2017 Nov;166(2):407--19.

  Simvastatin            Hyperlipidemia                                                                                                           HMGCR inhibitor                                                                    --Kou X, Yang Y, Jiang X, Liu H, Sun F, Wang X, et al. Vorinostat and Simvastatin have synergistic effects on triple-negative breast cancer cells via abrogating Rab7 prenylation. Eur J Pharmacol. 2017 Oct 15;813:161--71.\
                                                                                                                                                                                                                                     --Wolfe AR, Debeb BG, Lacerda L, Larson R, Bambhroliya A, Huang X, Bertucci F, Finetti P, Birnbaum D, Van Laere S, Diagaradjan P, Ruffell B, Trenton NJ, Chu K, Hittelman W, Diehl M, Levental I, Ueno NT, Woodward WA. Simvastatin prevents triple-negative breast cancer metastasis in pre-clinical models through regulation of FOXO3a. Breast Cancer Res Treat. 2015 Dec;154(3):495-508\
                                                                                                                                                                                                                                     --Kou X, Jiang X, Liu H, Wang X, Sun F, Han J, et al. Simvastatin functions as a heat shock protein 90 inhibitor against triple-negative breast cancer. Cancer Sci. 2018 Oct;109(10):3272--84.\
                                                                                                                                                                                                                                     --Jung HH, Lee S-H, Kim J-Y, Ahn JS, Park YH, Im Y-H. Statins affect ETS1-overexpressing triple-negative breast cancer cells by restoring DUSP4 deficiency. Sci Rep. 2016 08;6:33035\
                                                                                                                                                                                                                                     --Sulaiman A, McGarry S, Li L, Jia D, Ooi S, Addison C, et al. Dual inhibition of Wnt and Yes-associated protein signaling retards the growth of triple-negative breast cancer in both mesenchymal and epithelial states. Mol Oncol. 2018;12(4):423--40.\
                                                                                                                                                                                                                                     --Lacerda L, Reddy JP, Liu D, Larson R, Li L, Masuda H, Brewer T, Debeb BG, Xu W, Hortobágyi GN, Buchholz TA, Ueno NT, Woodward WA. Simvastatin radiosensitizes differentiated and stem-like breast cancer cell lines and is associated with improved local control in inflammatory breast cancer patients treated with postmastectomy radiation. Stem Cells Transl Med. 2014 Jul;3(7):849-56.\
                                                                                                                                                                                                                                     --Castellanos-Esparza YC, Wu S, Huang L, Buquet C, Shen R, Sanchez-Gonzalez B, et al. Synergistic promoting effects of pentoxifylline and simvastatin on the apoptosis of triple-negative MDA-MB-231 breast cancer cells. Int J Oncol. 2018 Apr;52(4):1246--54.\
                                                                                                                                                                                                                                     --Abdoul-Azize S, Buquet C, Li H, Picquenot J-M, Vannier J-P. Integration of Ca2+ signaling regulates the breast tumor cell response to simvastatin and doxorubicin. Oncogene. 2018;37(36):4979--93.\
                                                                                                                                                                                                                                     --Kanugula AK, Gollavilli PN, Vasamsetti SB, Karnewar S, Gopoju R, Ummanni R, et al. Statin-induced inhibition of breast cancer proliferation and invasion involves attenuation of iron transport: intermediacy of nitric oxide and antioxidant defence mechanisms. FEBS J. 2014 Aug;281(16):3719--38.\
                                                                                                                                                                                                                                     --Park YH, Jung HH, Ahn JS, Im Y-H. Statin induces inhibition of triple negative breast cancer (TNBC) cells via PI3K pathway. Biochem Biophys Res Commun. 2013 Sep 20;439(2):275--9.\
                                                                                                                                                                                                                                     --Koohestanimobarhan S, Salami S, Imeni V, Mohammadi Z, Bayat O. Lipophilic statins antagonistically alter the major epithelial-to-mesenchymal transition signaling pathways in breast cancer stem-like cells via inhibition of the mevalonate pathway. J Cell Biochem. 2018 Sep 6;

  Sodium Bicarbonate     Relief of wind and griping pains                                                                                                                                                                            --Abumanhal-Masarweh H, Koren L, Zinger A, Yaari Z, Krinsky N, Kaneti G, et al. Sodium bicarbonate nanoparticles modulate the tumor pH and enhance the cellular uptake of doxorubicin. J Control Release. 2019 Feb 28;296:1--13.

  Sulfasalazine          Rheumatoid arthritis; ulcerative colitis; active Crohn\'s Disease.                                                       Cyclooxygenase inhibitor                                                           --Hasegawa M, Takahashi H, Rajabi H, Alam M, Suzuki Y, Yin L, et al. Functional interactions of the cystine/glutamate antiporter, CD44v and MUC1-C oncoprotein in triple-negative breast cancer cells. Oncotarget. 2016 Mar 15;7(11):11756--69.\
                                                                                                                                                                                                                                     --Timmerman LA, Holton T, Yuneva M, Louie RJ, Padró M, Daemen A, et al. Glutamine sensitivity analysis identifies the xCT antiporter as a common triple-negative breast tumor therapeutic target. Cancer Cell. 2013 Oct 14;24(4):450--65

  Thioridazine           Psychotic disorders                                                                                                      Dopamine receptor antagonist                                                       --Tegowski M, Fan C, Baldwin AS. Thioridazine inhibits self-renewal in breast cancer cells via DRD2-dependent STAT3 inhibition, but induces a G1 arrest independent of DRD2. J Biol Chem. 2018 12;293(41):15977--90.\
                                                                                                                                                                                                                                     --Goyette M-A, Cusseddu R, Elkholi I, Abu-Thuraia A, El-Hachem N, Haibe-Kains B, et al. AXL knockdown gene signature reveals a drug repurposing opportunity for a class of antipsychotics to reduce growth and metastasis of triple-negative breast cancer. Oncotarget. 2019 Mar 12;10(21):2055--67

  Tigecycline            Infections                                                                                                               Bacterial 30S ribosomal subunit inhibitor                                          --Jones RA, Robinson TJ, Liu JC, Shrestha M, Voisin V, Ju Y, et al. RB1 deficiency in triple-negative breast cancer induces mitochondrial protein translation. J Clin Invest. 2016 03;126(10):3739--57

  Tocilizumab            Rheumatoid arthritis                                                                                                                                                                                        --Jin K, Pandey NB, Popel AS. Simultaneous blockade of IL-6 and CCL5 signaling for synergistic inhibition of triple-negative breast cancer growth and metastasis. Breast Cancer Res. 2018 14;20(1):54.\
                                                                                                                                                                                                                                     --Weng Y-S, Tseng H-Y, Chen Y-A, Shen P-C, Al Haq AT, Chen L-M, et al. MCT-1/miR-34a/IL-6/IL-6R signaling axis promotes EMT progression, cancer stemness and M2 macrophage polarization in triple-negative breast cancer. Mol Cancer. 2019 18;18(1):42.

  Trifluoperazine        Psychotic disorders                                                                                                      Dopamine receptor antagonist                                                       --Goyette M-A, Cusseddu R, Elkholi I, Abu-Thuraia A, El-Hachem N, Haibe-Kains B, et al. AXL knockdown gene signature reveals a drug repurposing opportunity for a class of antipsychotics to reduce growth and metastasis of triple-negative breast cancer. Oncotarget. 2019 Mar 12;10(21):2055--67.\
                                                                                                                                                                                                                                     --Feng Z, Xia Y, Gao T, Xu F, Lei Q, Peng C, et al. The antipsychotic agent trifluoperazine hydrochloride suppresses triple-negative breast cancer tumor growth and brain metastasis by inducing G0/G1 arrest and apoptosis. Cell Death Dis. 2018 Sep 26;9(10):1006.\
                                                                                                                                                                                                                                     --Fancy RM, Kim H, Napier T, Buchsbaum DJ, Zinn KR, Song Y. Calmodulin antagonist enhances DR5-mediated apoptotic signaling in TRA-8 resistant triple negative breast cancer cells. J Cell Biochem. 2018;119(7):6216--30.\
                                                                                                                                                                                                                                     --Park S-H, Chung YM, Ma J, Yang Q, Berek JS, Hu MC-T. Pharmacological activation of FOXO3 suppresses triple-negative breast cancer in vitro and in vivo. Oncotarget. 2016 Jul 5;7(27):42110--25.

  Valproic acid          Epilepsy                                                                                                                 HDAC inhibitor                                                                     --Sulaiman A, McGarry S, Lam KM, El-Sahli S, Chambers J, Kaczmarek S, et al. Co-inhibition of mTORC1, HDAC and ESR1α retards the growth of triple-negative breast cancer and suppresses cancer stem cells. Cell Death Dis. 2018 Jul 26;9(8):815.\
                                                                                                                                                                                                                                     --Tarasenko N, Chekroun-Setti H, Nudelman A, Rephaeli A. Comparison of the anticancer properties of a novel valproic acid prodrug to leading histone deacetylase inhibitors. J Cell Biochem. 2018;119(4):3417--28\
                                                                                                                                                                                                                                     --Prestegui-Martel B, Bermúdez-Lugo JA, Chávez-Blanco A, Dueñas-González A, García-Sánchez JR, Pérez-González OA, et al. N-(2-hydroxyphenyl)-2-propylpentanamide, a valproic acid aryl derivative designed in silico with improved anti-proliferative activity in HeLa, rhabdomyosarcoma and breast cancer cells. J Enzyme Inhib Med Chem. 2016;31(sup3):140--9\
                                                                                                                                                                                                                                     --Debeb BG, Lacerda L, Larson R, Wolfe AR, Krishnamurthy S, Reuben JM, et al. Histone deacetylase inhibitor-induced cancer stem cells exhibit high pentose phosphate pathway metabolism. Oncotarget. 2016 May 10;7(19):28329--39\
                                                                                                                                                                                                                                     --Wiegmans AP, Yap P-Y, Ward A, Lim YC, Khanna KK. Differences in Expression of Key DNA Damage Repair Genes after Epigenetic-Induced BRCAness Dictate Synthetic Lethality with PARP1 Inhibition. Mol Cancer Ther. 2015 Oct;14(10):2321--31

  Verapamil              Hypertension, angina pectoris                                                                                            Calcium channel blocker                                                            --Deshmukh RR, Kim S, Elghoul Y, Dou QP. P-Glycoprotein Inhibition Sensitizes Human Breast Cancer Cells to Proteasome Inhibitors. J Cell Biochem. 2017;118(5):1239--48

  Verteporfin            Exudative age-related macular degeneration                                                                               Photosensitising agent                                                             --Li Y, Wang S, Wei X, Zhang S, Song Z, Chen X, et al. Role of inhibitor of yes-associated protein 1 in triple-negative breast cancer with taxol-based chemoresistance. Cancer Sci. 2019 Feb;110(2):561--7.\
                                                                                                                                                                                                                                     --Kim J, Shamul JG, Shah SR, Shin A, Lee BJ, Quinones-Hinojosa A, et al. Verteporfin-Loaded Poly(ethylene glycol)-Poly(beta-amino ester)-Poly(ethylene glycol) Triblock Micelles for Cancer Therapy. Biomacromolecules. 2018 13;19(8):3361--70\
                                                                                                                                                                                                                                     --Andrade D, Mehta M, Griffith J, Panneerselvam J, Srivastava A, Kim T-D, et al. YAP1 inhibition radiosensitizes triple negative breast cancer cells by targeting the DNA damage response and cell survival pathways. Oncotarget. 2017 Nov 17;8(58):98495--508

  Warfarin               Prophylaxis of systemic embolism, of venous thrombosis and pulmonary embolism.                                           Vitamin K antagonist                                                               --Beaudin S, Kokabee L, Welsh J. Divergent effects of vitamins K1 and K2 on triple negative breast cancer cells. Oncotarget. 2019 Mar 19;10(23):2292--305

  Zoledronic acid        Osteoporosis, prophylaxis of skeletal fractures and treat hypercalcemia of malignancy, treat pain from bone metastases   Bone resorption inhibitor                                                          --Liu H, Wang S-H, Chen S-C, Chen C-Y, Lin T-M. Zoledronic acid blocks the interaction between breast cancer cells and regulatory T-cells. BMC Cancer. 2019 Feb 26;19(1):176.\
                                                                                                                                                                                                                                     --Cai X-J, Wang Z, Cao J-W, Ni J-J, Xu Y-Y, Yao J, et al. Anti-angiogenic and antitumor effects of metronomic use of novel liposomal zoledronic acid depletes tumor-associated macrophages in triple negative breast cancer. Oncotarget. 2017 Oct 13;8(48):84248--57\
                                                                                                                                                                                                                                     --Schech AJ, Kazi AA, Gilani RA, Brodie AH. Zoledronic acid reverses the epithelial-mesenchymal transition and inhibits self-renewal of breast cancer cells through inactivation of NF-κB. Mol Cancer Ther. 2013 Jul;12(7):1356--66\
                                                                                                                                                                                                                                     --Ibrahim T, Liverani C, Mercatali L, Sacanna E, Zanoni M, Fabbri F, et al. Cisplatin in combination with zoledronic acid: a synergistic effect in triple-negative breast cancer cell lines. Int J Oncol. 2013 Apr;42(4):1263--70\
                                                                                                                                                                                                                                     --Ibrahim T, Mercatali L, Sacanna E, Tesei A, Carloni S, Ulivi P, et al. Inhibition of breast cancer cell proliferation in repeated and non-repeated treatment with zoledronic acid. Cancer Cell Int. 2012 Nov 22;12(1):48.\
                                                                                                                                                                                                                                     --Gschwantler-Kaulich D, Weingartshofer S, Grunt TW, Mairhofer M, Tan Y, Gamper J, et al. Estradiol impairs the antiproliferative and proapoptotic effect of Zoledronic acid in hormone sensitive breast cancer cells in vitro. PLoS ONE. 2017;12(9):e0185566\
                                                                                                                                                                                                                                     --Tripathi R, Singh P, Singh A, Chagtoo M, Khan S, Tiwari S, et al. Zoledronate and Molecular Iodine Cause Synergistic Cell Death in Triple Negative Breast Cancer through Endoplasmic Reticulum Stress. Nutr Cancer. 2016 Jun;68(4):679--88.
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
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###### Characteristics of clinical studies about repurposing of old drugs for TNBC treatment.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reference                                       Study type                                                              Database used (if observational) and data source type                                                                 Country                Study period   Population                                                                   Main exclusion criteria                                                                                                       Drugs of interest
  ----------------------------------------------- ----------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------- ---------------------- -------------- ---------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------- ---------------------
  **Bayraktar *et al* 2012** \[[@ref10]\]         Retrospective study                                                     Breast Cancer Management System (Medical records and pharmacy data)                                                   USA                    1995--2007     Women with TNBC who received adjuvant chemotherapy                           --Metastatic or bilateral disease\                                                                                            Metformin
                                                                                                                                                                                                                                                                                                                                                                   --Prior history of cancer\                                                                                                    
                                                                                                                                                                                                                                                                                                                                                                   --Resolved gestational diabetes\                                                                                              
                                                                                                                                                                                                                                                                                                                                                                   --Diabetes diagnosed after adj chemotherapy                                                                                   

  **Botteri *et al* 2013** \[[@ref11]\]           Retrospective cohort study                                              Breast Cancer and Cardiology Division Databases of the European Institute of Oncology of Milan (Disease registries)   Italy                  1997--2008     Postmenopausal women operated for early primary TNBC                         History of invasive cancer or metastatic disease                                                                              Beta\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 blockers

  **Melhem-Bertrand *et al* 2011** \[[@ref12]\]   Retrospective cohort study                                              Breast Cancer Management System Database (Medical chart and pharmacy data)                                            USA                    1995--2007     Women with invasive TNBC treated with neoadjuvant anthracylines and taxane   --BB after neoadjuvant chemotherapy\                                                                                          Beta\
                                                                                                                                                                                                                                                                                                                                                                   --Unknown receptors expression status\                                                                                        blockers
                                                                                                                                                                                                                                                                                                                                                                   --Incomplete records longer than 9 months between neoadjuvant chemotherapy initiation and surgery\                            
                                                                                                                                                                                                                                                                                                                                                                   --Bilateral BC                                                                                                                

  **Spera *et al* 2017 (1)** \[[@ref13]\]         Retrospective cohort study                                              Data from a randomised, double blind clinical trial (ROSE/TRIO-012)                                                   Multicentric           --             Women with advanced TNBC                                                     --                                                                                                                            Beta\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 blockers

  **Spera *et al* 2017 (2)** \[[@ref13]\]         Retrospective cohort study                                              Data from a randomised, double blind clinical trial (BCIRG-005)                                                       Multicentric           --             Women with node positive TNBC                                                --                                                                                                                            Beta\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 blockers

  **Chan *et al* 2017** \[[@ref14]\]              Phase II, open label, single arm study                                  --                                                                                                                    --                     --             Women with stage II/III TNBC                                                 --Patients who have had chemotherapy or radiotherapy within 6 weeks prior to entering the study\                              Tetrathio-molybdate
                                                                                                                                                                                                                                                                                                                                                                   --Pregnant women                                                                                                              

  **Hasegawa *et al* 2015** \[[@ref15]\]          Phase II, open label, randomised study                                  --                                                                                                                    Multicentric (Japan)   2010--2012     Women with stage IIA/IIIB TNBC                                               --Bilateral breast cancer or inflammatory breast cancer\                                                                      Zoledronic acid
                                                                                                                                                                                                                                                                                                                                                                   --Distant metastasis\                                                                                                         
                                                                                                                                                                                                                                                                                                                                                                   --History of chemotherapy, endocrine therapy, or radiotherapy                                                                 

  **Ishikawa *et al* 2017** \[[@ref16]\]          Phase II, open label, randomised study                                  --                                                                                                                    Multicentric (Japan)   2010--2012     Women with stage IIA/IIIB TNBC                                               --Bilateral breast cancer or inflammatory breast cancer\                                                                      Zoledronic acid
                                                                                                                                                                                                                                                                                                                                                                   --Distant metastasis\                                                                                                         
                                                                                                                                                                                                                                                                                                                                                                   --History of chemotherapy, endocrine therapy, or radiotherapy                                                                 

  **Retsky *et al* 2012** \[[@ref17]\]            Retrospective study                                                     Data from medical records                                                                                             Belgium                2003--2008     Women who underwent mastectomy with axillary dissection                      --Previous ipsilateral surgery for breast cancer were excluded                                                                Ketorolac

  **Chow *et al* 2013** \[[@ref18]\]              Phase II, multicentre, open-label, single-arm study (OOTR-N001 study)   --                                                                                                                    --                     2006--2010     Women with primary breast cancer                                             --Distant metastasis\                                                                                                         Celecoxib
                                                                                                                                                                                                                                                                                                                                                                   --Multiple, bilateral breast cancer\                                                                                          
                                                                                                                                                                                                                                                                                                                                                                   --Postmenopausal patients with both positive estrogen and progesterone receptor status and negative lymph node involvement\   
                                                                                                                                                                                                                                                                                                                                                                   --Pregnant women or women with suspected pregnancy\                                                                           
                                                                                                                                                                                                                                                                                                                                                                   --Prior history of invasive breast cancer                                                                                     

  **Shiao *et al* 2017** \[[@ref19]\]             Retrospective study                                                     Data from University of texas Southwestern (UTSW) TNBC registry (Medical records)                                     USA                    1998--2016     Women with stageII/III TNBC                                                  --Stage I patients                                                                                                            Aspirin/Clopidogrel

  **Williams 2018** \[[@ref20]\]                  Retrospective study                                                     Electronical medical records                                                                                          USA                    2005--2013     Women with primary operable stages I-III breast cancer                       --Not clear use of aspirin\                                                                                                   Aspirin
                                                                                                                                                                                                                                                                                                                                                                   --Not surgery\                                                                                                                
                                                                                                                                                                                                                                                                                                                                                                   --Not primary\                                                                                                                
                                                                                                                                                                                                                                                                                                                                                                   --Lack of follow up                                                                                                           

  **Pierga *et al* 2010** \[[@ref21]\]            Phase II, randomised study (Remagus 02)                                 --                                                                                                                    --                     2004--2000     Women with stageII/III breast cancer                                         --                                                                                                                            Celecoxib

  **Tsubamoto *et al* 2014** \[[@ref22]\]         Retrospective study                                                     Kohnan hospitals (Medical records)                                                                                    Japan                  2008--2012     Women with TNBC                                                              --Visceral (lungs, brain, and liver) metastasis                                                                               Itraconazole

  **Wang *et al* 2015** \[[@ref23]\]              Phase II, open label, randomised study                                  --                                                                                                                    --                     --             Women with metastatic or recurrent breast cancer                             --Brain metastases\                                                                                                           Esomeprazol
                                                                                                                                                                                                                                                                                                                                                                   --Prior chemotherapy in the metastatic setting                                                                                

  **Nanda *et al* 2016** \[[@ref24]\]             Phase I, randomised                                                     --                                                                                                                    USA                    --             Metastatic or locally advanced breast cancer                                 --Allergy or hypersensitivuty to mifepristone, paclitaxel\                                                                    Mifepristone
                                                                                                                                                                                                                                                                                                                                                                   --Received more than 4 prior cytotoxic therapies for metastatic disease or prior nab-paclitaxel or mifepistone.\              
                                                                                                                                                                                                                                                                                                                                                                   --Pregnant or breast feeding                                                                                                  

  **Lacerda *et al* 2014** \[[@ref25]\]           Retrospective study                                                     IBC database - Breast Cancer Management System at MD Anderson Cancer Center (Medical records)                         USA                    1995--2011     Patients with Inflammatory breast cancer                                     --Stage IV patients\                                                                                                          Statins
                                                                                                                                                                                                                                                                                                                                                                   --Patients who did not receive adj postmastectomy radiotherapy\                                                               
                                                                                                                                                                                                                                                                                                                                                                   --Patients with locoregional recurrence prior to radiation                                                                    

  **Shaitelman *et al* 2017** \[[@ref26]\]        Retrospective study                                                     Data from MD Anderson Cancer Center (Medical records)                                                                 USA                    1997--2012     Women with invasive, non-metastatic TNBC\                                    --                                                                                                                            Statins
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### Outcomes for each clinical study.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reference                                   ARM1                                                                                  ARM2                                                                                  ARM3                              Population size (TNBC)           Average age (years) of TNBC patients   Follow up                 Outcome                                   Outcome size                                                                                                     Effect size measures
  ------------------------------------------- ------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------- --------------------------------- -------------------------------- -------------------------------------- ------------------------- ----------------------------------------- ---------------------------------------------------------------------------------------------------------------- --------------------------------------------------------
  Bayraktar *et al* 2012 \[[@ref10]\]         Diabetic patients\                                                                    Diabetic patients\                                                                    Not\                              1,448 patients\                  ARM1: Median 53\                       62 months                 1\) Distant metastasis free survival\     1\) ARM1, ARM2, ARM3 0.73 (0.58--0.83), 0.66 (0.52--0.77), 0.60 (0.57--0.62); p = 0.23\                          --Five years estimates rates between the three groups\
                                              **Metformin + Adj chemo +**\                                                          **Adj chemo alone**\                                                                  diabeticpatients                  --ARM1: 63\                      ARM2: Median 51\                                                 2) Overall survival\                      1) ARM2 versus ARM1: 1.63 (95% CI: 0.87--3.06) p = 0.13; ARM3 versus ARM1: 1.62 (95%CI: 0.97--2.71) p = 0.06\    --Hazard ratio
                                              Adj chemo:\                                                                           Adj chemo:\                                                                                                             --ARM2: 67\                      ARM3: Median 58                                                  3) Recurrence free survival               2) ARM1, ARM2, ARM3: 0.65 (0.51--0.76), 0.64 (0.5--0.75), 0.54 (0.51--0.56); p = 0.38\                           
                                              --anthracycline +/- taxane\                                                           --anthracycline +/- taxane\                                                                                             --ARM3: 1,318                                                                                                                               2) ARM2 versus ARM1: 1.37 (95% CI: 0.78--2.40) p = 0.27; ARM3 versus ARM1: 1.36 (95% CI: 0.87--2.10) p = 0.17\   
                                              --single-agent taxane\                                                                --single-agent taxane\                                                                                                                                                                                                                                              3) ARM1, ARM2, ARM3: 0.67 (0.52--0.79) 0.69 (0.55--0.79), 0.66 (0.63--0.69); p = 0.58\                           
                                              --other                                                                               --other                                                                                                                                                                                                                                                             3) ARM2 versus ARM1: 1.22 (95% CI: 0.66--2.28) p = 0.52; ARM3 versus ARM1: 1.28 (95% CI: 0.79--2.08) p = 0.31    

  Botteri *et al* 2013 \[[@ref11]\]           **Beta blockers users**                                                               **Beta blockers non users**                                                           --                                800 patients                     ARM1: Mean 62\                         ARM1: median 72 months\   1\) Breast Cancer-related events\         1\) 13,6% versus 27.9%; p = 0.015\                                                                               --Five-year cumulative incidence\
                                                                                                                                                                                                                                                                                             ARM2: Mean 59                          ARM2: median 68 months    2) Distant metastasis\                    2) 0.32 (95% CI: 0.12--0.90; p = 0.031)\                                                                         --Hazard ratio
                                                                                                                                                                                                                                                                                                                                                              3) Breast Cancer death                    3) 0.42 (95% CI: 0.18--0.97; p = 0.042)                                                                          

  Melhem-Bertrand *et al* 2011 \[[@ref12]\]   **Beta blockers +** neoadj therapy                                                    **Beta blockers non users**                                                           --                                1.417 patients\                  ARM1: Mean 47.5\                       ARM1: Median 55 months\   1\) Recurrence free survival\             1\) 0.30; 95% CI: 0.10--0.87; p = 0.027\                                                                         Hazard ratio
                                                                                                                                                                                                                                                            --ARM1: 102\                     ARM2: Mean 55                          ARM2: Median 63 months    2) Overall survival                       2) 0.35; 95% CI: 0.12--1.00; p = 0.05                                                                            
                                                                                                                                                                                                                                                            --ARM2: 1311                                                                                                                                                                                                                                                 

  Spera *et al* 2017 1 \[[@ref13]\]           **Beta blockers users**                                                               **Beta blockers non users**                                                           --                                1144 patients\                   ARM1: Median 60\                       Median: 25.1 months       1\) Progression free survival\            1\) 0.52; 95%CI: 0.34--0.80; p = 0.002\                                                                          Hazard ratio
                                                                                                                                                                                                                                                            --ARM1: 152\                     ARM2: Median 53                                                  2) Overall survival                       2) 0.87; 95%CI: 0.58--1.31; p = 0.504                                                                            
                                                                                                                                                                                                                                                            --ARM2: 991                                                                                                                                                                                                                                                  

  Spera *et al* 2017 - 2 \[[@ref13]\]         **Beta blockers users**                                                               **Beta blockers non users**                                                           --                                35 patients                      --                                     --                        1\) Relapse free survival\                1\) 0.69; 95%CI: 0.35--1.34; p = 0.269\                                                                          Hazard ratio
                                                                                                                                                                                                                                                                                                                                                              2) Overall survival                       2) 0.73; 95%CI: 0.35--1.48; p = 0.384                                                                            

  Chan *et al* 2017 \[[@ref14]\]              Tetramyolibdate                                                                       --                                                                                    --                                36 patients                      --                                     Median 6.3 years          Event free survival                       Stage II/III patients 90% (95% CI: 78%--100%)\                                                                   Two-year event free rate
                                                                                                                                                                                                                                                                                                                                                                                                        Stage IV patients: 69% (95% CI: 49%--96%)                                                                        

  Hasegawa *et al* 2015 \[[@ref15]\]          **Zoledronic acid + Neoadj chemotherapy**\                                            **Chemotherapy alone**\                                                               --                                34 patients                      --                                     --                        Pathological complete response rates      ARM1: 6/17(35.3%) CI: 12.6--58.0; ARM2: 2/17(11.8%) CI: 0.0--27.1; p = 0.112                                     Pathological complete response rates
                                              Chemotherapy:\                                                                        Chemotherapy:\                                                                                                                                                                                                                                                                                                                                                                       
                                              Four cycles of FEC100 every 3 weeks followed by 12 cycles of paclitaxel at 80 mg/m2   Four cycles of FEC100 every 3 weeks followed by 12 cycles of paclitaxel at 80 mg/m2                                                                                                                                                                                                                                                                                                  

  Ishikawa *et al* 2017 \[[@ref16]\]          Zoledronic acid + Neoadj chemotherapy\                                                **Chemotherapy alone**\                                                               --                                34 patients                      --                                     --                        Three years disease free survival         ARM1: 94.1%; ARM2: 70.6%; p = 0.077                                                                              Percentage
                                              Chemotherapy:\                                                                        Chemotherapy:\                                                                                                                                                                                                                                                                                                                                                                       
                                              Four cycles of FEC100 followed by paclitaxel                                          Four cycles of FEC100 followed by paclitaxel                                                                                                                                                                                                                                                                                                                                         

  Retsky *et al* 2012 \[[@ref17]\]            **Ketorolac + Chemotherapy**\                                                         **Chemotherapy alone**\                                                               --                                Not specified                    --                                     27.3 months               Disease free survival                     Far superior disease-free survival in the first few years after surgery (no data shown)                          --
                                              \                                                                                     \                                                                                                                                                                                                                                                                                                                                                                                    

  Chow *et al* 2013 \[[@ref18]\]              **Celecoxib (200mg) + Neoadj chemo:**\                                                --                                                                                    --                                2 patients                       --                                     --                        1\) Pathological complete response\       1\) 0%\                                                                                                          Percentage
                                              \                                                                                                                                                                                                                                                                                                               2) Near Pathological complete response    2) 50%                                                                                                           
                                              Chemotherapy: Four cycles of FEC followed by four cycles of docetaxel\                                                                                                                                                                                                                                                                                                                                                                                                     

  Shiao *et al* 2017 \[[@ref19]\]             Antiplatelet users + Possible chemotherapy                                            Not antiplatelet users + Possible chemotherapy                                        --                                222 patients\                    ARM1: Median 55\                       ARM1: Median: 41.3\       1\) Five years Disease free survival\     1\) ARM1: 80.4%; ARM2: 62.3%; 0.503 (0.261--0.970) p = 0.04\                                                     --Percentage\
                                                                                                                                                                                                                                                            --ARM1 65\                       ARM2: Median 50                        ARM2: Median 40.9         2) Five years Overall survival\           2) ARM1: 77.2%; ARM2: 69%;0.652 (0.343--1.239) p = 0.192\                                                        --Hazard ratio
                                                                                                                                                                                                                                                            --ARM2 157                                                                                        3) Five years Distant metastasis rate     3) ARM1: 8.8%; ARM2: 31.9%; 0.310 (0.132--0.729) p = 0.007                                                       

  Williams *et al* 2018 \[[@ref20]\]          **Aspirin users + Possible chemotherapy**                                             **Not aspirin users + Possible chemotherapy**                                         --                                147 patients\                    --                                     --                        1\) Overall survival\                     No specific outcome for TNBC comparing ARM1 versus ARM2                                                          Hazard ratio
                                                                                                                                                                                                                                                            --ARM1: 33\                                                                                       2) Disease free survival                                                                                                                                   
                                                                                                                                                                                                                                                            --ARM2: 114\                                                                                                                                                                                                                                                 

  Pierga *et al* 2010 \[[@ref21]\]            **Celecoxib + Chemotherapy**\                                                         **Chemotherapy**\                                                                     --                                78 patients\                     --                                     --                        Pathological complete response            29.5% (95% CI: 19.7%--40.9%)                                                                                     Pathological complete response rates
                                              Chemotherapy:\                                                                        Chemotherapy:\                                                                                                          --ARM1: 44\                                                                                                                                                                                                                                                  
                                              Eight cycles of EC-D                                                                  Eight cycles of EC-D                                                                                                    --ARM2: 34                                                                                                                                                                                                                                                   

  Tsubamoto *et al* 2014 \[[@ref22]\]         **Itraconazole + Chemotherapy**\                                                      --                                                                                    --                                13 patients                      Median: 45                             --                        1\) Response rates\                       1\) 62% (95% CI: 35%--88%)\                                                                                      Pathological complete response rates
                                              \                                                                                                                                                                                                                                                                                                               2) Progression free survival\             2) 10.8 months (95% CI: 7.6--15.3 months)\                                                                       
                                              Chemotherapy :\                                                                                                                                                                                                                                                                                                 3) Overall survival                       3) 20.4 months (95% CI: 13.1--41.4 months)                                                                       
                                              docetaxel, carboplatin, and gemcitabine, vinorelbine, bevacizumab                                                                                                                                                                                                                                                                                                                                                                                                          

  Wang *et al* 2015 \[[@ref23]\]              **Esomeprazole low dose (80mg) + chemotherapy**\                                      **Esomeprazole high dose (100mg) + chemotherapy**\                                    **Chemotherapy**\                 15 patients\                     --                                     --                        Time to progression                       1\) 10.7 (ARM1+ARM2) and 5.8 months (ARM3); p = 0.011                                                            Median time
                                              Chemotherapy:\                                                                        Chemotherapy:\                                                                        Docetaxel followed by cisplatin   --ARM1: 2\                                                                                                                                                                                                                                                   
                                              Docetaxel followed by cisplatin                                                       Docetaxel followed by cisplatin                                                                                         --ARM2: 6\                                                                                                                                                                                                                                                   
                                                                                                                                                                                                                                                            --ARM3: 7                                                                                                                                                                                                                                                    

  Nanda *et al* 2016 \[[@ref24]\]             **Mifepristone (300mg) + Paclitaxel**\                                                **Mifepristone (300mg) + Paclitaxel**\                                                **Placebo**                       4 patients\                      --                                     --                        Treatment response                        Three patients have partial response, and one patient complete response                                          --
                                                                                                                                                                                                                                                            --No information on treatments                                                                                                                                                                                                                               

  Lacerda et al 2014 \[[@ref25]\]             Statins + Postmastectomy radiation                                                    Postmastectomy radiation                                                              --                                --ARM1: 16\                      --                                     Median: 2.5 years         3 years Risk of locoregional recurrence   No specific outcome for TNBC                                                                                     --
                                                                                                                                                                                                                                                            --ARM2: 86                                                                                                                                                                                                                                                   

  Shaitelman *et al* 2017 \[[@ref26]\]        **Statin users**                                                                      **Statin users** (patients with lipid/cholesterol values)                             Not statin users                  -ARM1: 293\                      --                                     Median: 75.1 months       ARM1 versus ARM3\                         1\) 0.82 (95% CI: 0.57--1.16)\                                                                                   Relative risk
                                                                                                                                                                                                                                                            -ARM2: 576\                                                                                       1)Recurrence\                             2) 0.70 (95% CI: 0.47--1.03)\                                                                                    
                                                                                                                                                                                                                                                                                                                                                              2)BCa Death\                              3) 0.60 (95% CI: 0.36--1.03)\                                                                                    
                                                                                                                                                                                                                                                                                                                                                              ARM2 versus ARM3\                         4) 0.51 (95% CI: 0.28--0.93)\                                                                                    
                                                                                                                                                                                                                                                                                                                                                              3)Recurrence\                                                                                                                                              
                                                                                                                                                                                                                                                                                                                                                              4)BCa Death\                                                                                                                                               
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### Ongoing trials found in Clinicaltrials.gov.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Drugs (REDO_DB)        Main indication                                                                                                          Mechanism of action                                                                Clinical trial.gov
  ---------------------- ------------------------------------------------------------------------------------------------------------------------ ---------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------
  Acetylsalicylic acid   Analgesia, swelling, prophylaxis of venous embolism and further heart attacks or strokes                                 Cyclooxygenase inhibitor                                                           \(3\)

  Atorvastatin           Coronary heart disease, acute coronary syndrome                                                                          HMGCR inhibitor                                                                    NCT03358017 (Recruitment Status : Recruiting);\
                                                                                                                                                                                                                                     NCT03872388 (Recruitment Status : Recruiting);\
                                                                                                                                                                                                                                     NCT02201381 (Recruitment Status : Recruiting)

  Celecoxib              OA, RA, JRA, AS, acute pain, primary dysmenorrhea                                                                        Cyclooxygenase inhibitor                                                           NCT03599453 (Recruitment Status : Recruiting)

  Doxycycline            Respiratory/urinary tract/ophtalmic infection                                                                            Metalloproteinase inhibitor                                                        NCT02201381 (Recruitment Status : Recruiting)

  Epalrestat             Diabetes                                                                                                                 Aldose reductase inhibitor                                                         NCT03244358 (Recruitment Status : Recruiting)

  Flucytosine            Candida and/or Cryptococcus                                                                                              Other antifungal                                                                   NCT02576665 (Recruitment Status : Active)

  Imipramine             Depression                                                                                                               Norepinephrine reputake inhibitor\|serotonin reuptake inhibitor                    NCT03122444 (Recruitment Status : Not yet recruiting)

  Indomethacin           Analgesia                                                                                                                Cyclooxygenase inhibitor                                                           NCT02950259 (Recruitment Status : Active)

  Lansoprazole           Antacid                                                                                                                  ATPase inhibitor                                                                   NCT03794596 (Recruitment Status : Not yet recruiting)

  Leflunomide            Arthritis                                                                                                                Dihydroorotate dehydrogenase inhibitor\|PDGFR tyrosine kinase receptor inhibitor   NCT03709446 (Recruitment Status : Recruiting)

  Mebendazole            Parasitic infection                                                                                                      Tubulin polymerisation inhibitor                                                   NCT02201381 (Recruitment Status : Recruiting)

  Metformin              Diabetes                                                                                                                 Insulin sensitizer                                                                 NCT01650506 (Recruitment Status : Completed); NCT02201381 (Recruitment Status : Recruiting)

  Mifepristone           Abortifacient                                                                                                            Glucocorticoid receptor ntagonist\|progesterone receptor antagonist                NCT02788981 (Recruitment Status : Recruiting)\
                                                                                                                                                                                                                                     NCT02014337 (Recruitment Status : Completed)

  Omeprazole             Antacid                                                                                                                  ATPase inhibitor                                                                   NCT02950259 (Recruitment Status : Active)

  Ritonavir              Anti-retroviral                                                                                                          HIV protease inhibitor                                                             NCT01009437 (Recruitment Status : Completed)

  Zoledronic acid        Osteoporosis, prophylaxis of skeletal fractures and treat hypercalcemia of malignancy, treat pain from bone metastases   Bone resorption inhibitor                                                          NCT03358017 (Recruitment Status : Recruiting);\
                                                                                                                                                                                                                                     NCT02595138 (Recruitment Status : Active)\
                                                                                                                                                                                                                                     NCT02347163 (Recruitment Status : Stopped due to the low accrual rate))
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
